Ipamorelin

Ipamorelin is documented as a synthetic pentapeptide and growth-hormone secretagogue, with the literature development code NNC 26-0161. That code identifies the reference compound in the literature; it is never a batch number. The declared sequence is Aib-His-D-2-Nal-D-Phe-Lys-NH2. Aib, D-2-Nal and D-Phe are non-proteinogenic or D-configured components, while the Lys-NH2 ending defines the amidated C-terminus.

Sequence and terminal form must be assessed together. The formula and mass below are assigned specifically to the amidated form, rather than presented as free-standing values. Database identifiers define a reference identity, but cannot authenticate experimental material or a supplied batch.

A literature reference, a database record and a catalogue identifier answer different questions. Matching supplied material to this reference identity requires released documentation tied to the physical batch.

Identity source: Raun et al. 1998 · PMID 9849822

Ipamorelin is classified as a GHSR-1a agonist within the ghrelin/GHS-receptor secretagogue class. This is distinct from GHRH analogues, including tesamorelin, which act through the GHRH receptor. The distinction is scientific classification only and does not predict results across research systems.

The authors' description of the first selective GH secretagogue must remain attached to that experimental comparison. It cannot be expanded beyond the controls, methods and variables reported in the publication. Likewise, receptor classification cannot establish the sequence, purity or molecular form of a later batch.

Mechanism source: Raun et al. 1998 · PMID 9849822 · DOI 10.1530/eje.0.1390552

This section describes findings in controlled research. The records span receptor systems, preclinical rodent models, human pharmacokinetic-pharmacodynamic modelling and a randomised controlled human study. Compound-name agreement does not merge their populations, methods or interpretive reach.

The unchanged findings in Johansen 1999 and the non-significant primary finding in Beck 2014 remain integral to this evidence map. Neither may be recast as confirmation.

Study sources: Raun 1998 · Gobburu 1999 · PMID 10496658 · Johansen 1999 · Svensson 2000 · Andersen 2001 · Venkova 2009 · Greenwood-Van Meerveld 2012 · Beck 2014

Four evidence levels require four separate scopes. Receptor-system observations remain assay-bound. Preclinical rodent records remain species- and design-bound. Human pharmacokinetic-pharmacodynamic modelling remains tied to its sampled population and analytical model. The randomised controlled human record remains a separate study, and its primary finding was not statistically significant.

The scientific class boundary must also remain intact: a ghrelin/GHS-receptor agonist is not a GHRH analogue merely because both classes appear in growth-hormone research. Class terminology does not establish equivalence between ipamorelin and tesamorelin or support an outcome statement.

Database identity, experimental material and supplied material form three distinct documentation levels. PubChem CID 9831659 describes a database reference. A publication reports the material characterised within its own methods. A supplied batch requires its own matching label, batch code, released specification and analytical record. A publication about a reference compound cannot prove that later supplied material has the same identity.

The cited literature does not establish the stated content, purity, salt or supplied form, storage conditions or stability of the catalogue material. Those points require product and batch records; none may be inferred from receptor terminology, model findings or database identifiers.

Boundary sources: Beck et al. 2014 · PMID 25331030

A stored German catalogue meta description records “lyophilised”, but confirmation against the released specification remains outstanding. It is therefore a catalogue entry awaiting confirmation, not an assured property. Salt or supplied form, stated content, storage conditions and stability period are open documentary points and are not asserted here.

The required documentation chain should connect Ipamorelin, SKU IP10, the label, batch code, released specification, analytical method, report identifier and result. A COA should identify the tested batch and the material to which each result applies. The presence of a released COA for the offered batch is not asserted on this page.

Any numerical purity statement must be batch-specific and supported by the corresponding COA. HPLC can document a method-specific chromatographic result for the analysed sample, but does not by itself establish every identity question. Identity evidence and chromatographic assessment are complementary, and results cannot be transferred between batches.

Ipamorelin is presented to EU laboratories as research material. Literature and database records provide reference context; neither replaces a released specification or matching batch documentation.

Research use only. For laboratory research only. Not for human or veterinary use. Not intended to diagnose, treat, cure or prevent any disease. Not a medicinal product, food or cosmetic.